Lyme Tests Launch
Launch of EpitogenX’s Advanced Lyme Disease Diagnostic Kit
We are thrilled to announce the launch of its cutting-edge Lyme Disease Diagnostic Kit. This advanced diagnostic tool is set to revolutionize Lyme disease research by offering unprecedented accuracy, reliability, and ease of use.
Background
Lyme disease, caused by the Borrelia burgdorferi sensu lato (s.l.) complex, remains a growing concern. Each year, approximately 600,000 cases are reported across the United States and Europe. Existing diagnostic methods primarily rely on symptom-based assessments, serology testing, and exposure risk evaluation. However, these methods have several limitations, especially during the early stages of infection when rapid diagnosis is crucial.
EpitogenX’s Peptide-Precision Platform
To overcome the limitations of existing tests, we have developed a Lyme test utilizing a peptide-precision platform. This innovative strategy combines EpitoPredikt™ and Epitogen® technologies to identify and multiplex immunodominant-epitopes.
Harnessing 120 Immunodominant Epitopes from 37 Borrelia Antigens
Our test utilizes 120 seropositive immunodominant epitopes derived from 37 Borrelia antigens, representing the main pathogenic species; B. burgdorferi, B. afzelii, B. garinii, and B. mayonii. These epitopes form the basis of chimeric antigens that power the Lyme antibody test.
Key Features of the Lyme Kit:
- High Sensitivity and Specificity: Designed to deliver precise results, minimizing false positives and negatives, crucial for the accurate study of Lyme disease.
- Flexibility to Modify Antigen: we can customize the antigen to target a specific bacterial strain and relevant research objectives.
- Cost-Effective: Priced competitively to ensure accessibility for a wide range of research laboratories, making high-quality diagnostics more affordable.
Dr. Ayham Alnabulsi, Chief Technology Officer at EpitogenX, stated, “We are excited to introduce this highly advanced diagnostic kit to the research community. Our team has worked tirelessly to ensure that it meets the highest standards of accuracy and reliability. This kit represents a significant leap forward in Lyme disease research and has the potential to greatly enhance our understanding and management of this complex disease.”
The launch of the Lyme Disease Diagnostic Kit for RUO marks a significant milestone in our ongoing commitment to advancing medical research and improving diagnostic tools. We invite research institutions, laboratories, and scientists to explore the capabilities of our new kit and contribute to the global effort in combating Lyme disease.
For more information, please visit our Lyme product page.
For enquiries and orders, please email us at info@epitogenx.com.